A new trick for an old drug: mTOR inhibitor rapamycin augments the effect of fluorouracil on hepatocellular carcinoma by inducing cell senescence

Cancer Biology and Therapy

Volumn 7, Issue 3, 2008, Pages 397-398

  Shi, Yufang ^a   August, David A ^b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Cell senescence; Fluorouracil; Hepatocellular carcinoma; Rapamycin

Indexed keywords

FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN;

CANCER CELL; CANCER RISK; DRUG EFFECT; DRUG MECHANISM; LIVER CELL CARCINOMA; NOTE; PROTEIN FUNCTION; RISK FACTOR; SENESCENCE; SIGNAL TRANSDUCTION;

EID: 45349091702     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.3.5871     Document Type: Note

References (14)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-6.
2. Ferlay J, Bray F, Pisani PY, Parkin DM. GLOBOCAN 2002; CancerIncidence, Mortality and Prevalence Worldwide. Lyon; France: IARCPress; 2004.
3. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis. 2005;25:143-54.
4. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5-S16.
5. Kulik LM. Advancements in hepatocellular carcinoma. Curr Opin Gastroenterol. 2007;23:268-74.
6. Nissen NN, Cavazzoni E, Tran TT, Poordad FP. Emerging role of transplantation for primary liver cancers. Cancer J. 2004;10:88-96.
7. Cha CH, Ruo L, Fong Y, et al. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg. 2003;238:315-321; discussion 321-313.
8. Ganne-Carrie N, Trinchet JC. Systemic treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2004;16:275-81.
9. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis. 2005;25:212-25.
10. Bu XX, Le C, Jia FQ, et al. Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells. Cancer Biology and Therapy. 2008:In Press.
11. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist. 2007;12:1007-18.
12. Aronica SM, Gingras AC, Sonenberg N, Cooper S, Hague N, Broxmeyer HE. Macrophage inflammatory protein-1alpha and interferon-inducible protein 10 inhibit synergistically induced growth factor stimulation of MAP kinase activity and suppress phosphorylation of eukaryotic initiation factor 4E and 4E binding protein 1. Blood. 1997;89:3582-95.
13. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol. 2003;3:371-377.
14. Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res. 1995;55:1982-8.